Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Ascendis Pharma A/S (ASND) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Ascendis Pharma A/S is one of 1003 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Ascendis Pharma A/S is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for ASND's full-year earnings has moved 15.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Based on the most recent data, ASND has returned 11.8% so far this year. At the same time, Medical stocks have lost an average of 4.4%. As we can see, Ascendis Pharma A/S is performing better than its sector in the calendar year. Another stock in the Medical sector, Benitec Biopharma Limited (BNTC), has outperformed the sector so far this year. The stock's year-to-date return is 8.3%. For Benitec Biopharma Limited, the consensus EPS estimate for the current year has increased 57.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Ascendis Pharma A/S belongs to the Medical - Biomedical and Genetics industry, which includes 509 individual stocks and currently sits at #75 in the Zacks Industry Rank. This group has lost an average of 6.7% so far this year, so ASND is performing better in this area. Benitec Biopharma Limited is also part of the same industry. Investors interested in the Medical sector may want to keep a close eye on Ascendis Pharma A/S and Benitec Biopharma Limited as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ascendis Pharma A/S (ASND):Free Stock Analysis Report Benitec Biopharma Limited (BNTC):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...